Skip to main content

Table 1 Clinical characteristics of patients with low ACLY expression

From: Low expression of ACLY associates with favorable prognosis in acute myeloid leukemia

Variable Low expression High expression P value
Number 58 216  
ACLY, median (range) 0.14 [0.12, 0.16] 0.33 [0.25, 0.40] < 0.001
Sex, female, n (%) 38 (65.5) 134 (62.0) 0.650
Age, median (range), years 45.50 [31.50, 62.75] 49.00 [35.00, 60.00] 0.468
WBC, median (IQR), ×109/L 13.55 [4.03, 34.00] 25.20 [5.65, 87.00] 0.010
HB, median (IQR), g/L 87.00 [73.00, 102.00] 78.80 [65.00, 97.00] 0.044
PLT, median (IQR), ×109/L 42.50 [22.00, 70.75] 42.00 [21.00, 77.00] 0.980
BM blast, median (IQR), % 65.75 [49.62, 81.25] 70.14 [52.34, 84.25] 0.541
FAB classification, n (%)    0.166
 M0 3 (5.2) 21 (9.7)  
 M1 7 (12.1) 20 (9.3)  
 M2 29 (50.0) 86 (39.8)  
 M4 6 (10.3) 20 (9.3)  
 M5 11 (19.0) 62 (28.7)  
 M6 2 (3.4) 1 (0.5)  
 AML 0 (0.0) 6 (2.8)  
Cytogenetic risks, n (%)    0.110
 Favorable 9 (15.5) 15 (6.9)  
 Intermediate 42 (72.4) 177 (81.9)  
 Poor 7 (12.1) 24 (11.1)  
Gene mutations, n (%)
 FLT3-ITD 6 (11.5) 30 (14.6) 0.660
 CEBPADM 10 (20.0) 10 (5.0) 0.002
 NPM1 12 (22.2) 56 (26.7) 0.602
 DNMT3A 1 (1.8) 23 (10.8) 0.035
Treatment, n (%)a    0.982
 DA 22 (37.9) 78 (36.1)  
 HAA 17 (29.3) 63 (29.2)  
 IA 19 (32.8) 75 (34.7)  
  1. WBC white blood cell, HB hemoglobin, PLT platelet counts, BM bone marrow, FAB French–American–British classification systems, DM double-allele, IQR interquantile
  2. aThe protocols used for induction therapy in different groups including HAA, homoharringtonine-based treatment (homoharringtonine 2 mg/m2/day for 3 days, cytarabine 75 mg/m2 twice daily for 7 days, aclarubicin 12 mg/m2 daily for 7 days) regiment; DA, daunorubicin 45 mg/m2 daily for 3 days and cytarabine 100 mg/m2 daily for 7 days; IA, idarubicin 6–8 mg/m2 daily for 7 days and aclarubicin 20 mg/m2 daily for 5 days